Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Polygenic risk / GWAS loci Genes (not modifiable) | Prevention |
Mixed
whyThe study's own results point different ways: the polygenic score added to APOE for predicting AD/MCI and for progression from amyloid-positive MCI to AD, but amyloid deposition was predicted by APOE alone. |
Prediction of AD, MCI, amyloid deposition and MCI-to-AD progression (AUC) by polygenic risk score with and without APOE | case-control study | 770 | AD and MCI are predicted by both APOE genotype and PRS (area under the curve [AUC] = 0.82% and 68%, respectively). Amyloid deposition is predicted by APOE only (AUC = 79%). Further progression to AD of individuals with MCI and amyloid-positive status is predicted by PRS over and above APOE (AUC = 67%) |
Annals of Neurology
2019 ✓ Peer-reviewed PMID 31199530 |
| Rare copy-number variants (22q11.21 dosage, ABCA1 / ABCA7 deletions) Genes (not modifiable) | Prevention |
Mixed
whyThe two kinds of variant point opposite ways: deletions and loss-of-function alleles in ABCA1 and ABCA7 and 22q11.21 deletions raised AD risk, while 22q11.21 duplication lowered it (odds ratio 0.34 at exome-wide significance in replication). Not modifiable. |
Alzheimer's disease case status (early- and late-onset) by rare copy-number variant burden and 22q11.21 dosage | case-control study | 22,319 | ABCA1 (odds ratio [OR] = 5.77 [95% confidence interval 2.25; 17.06], p = 0.0002) and ABCA7 deletions contribute to this deletion burden (OR = 2.29 [1.44; 3.65], p = 0.0006), while CTSB LoF alleles appear as candidates (OR = 5.03 [1.50; 20.71], p = 0.0089) ... Replication in 33,977 affected individuals and 362,322 control subjects confirmed association for 22q11.21 dosage with exome-wide significance (ORSCARF2 = 0.34 [0.21; 0.53]; mega-p value = 5.52 × 10-7) |
American Journal of Human Genetics
2026 ✓ Peer-reviewed PMID 42648288 |